RxDoctor Payments Data

Rahul Gandhi, MD

Internal Medicine · Washington, DCNPI 1215356191

Payments from drug & device makers

$345in general payments, 2019–2025

Across 14 payments — averaging $24.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$78
  • Pfizer$64
  • Teva Pharmaceuticals USA, Inc.$55
  • Novartis$31
  • Merck$28
  • TMS Neurohealth Centers Inc.$28
  • plus $62 from 3 others

What the payments were for

  • Food & beverage$345100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk3$78
Pfizer3$64
Teva Pharmaceuticals USA, Inc.2$55
Novartis1$31
Merck1$28
TMS Neurohealth Centers Inc.1$28
Xeris Pharmaceuticals, Inc.1$23
Amgen1$20
Lilly USA, LLC1$19

How this compares

$345 in reported general payments places this provider in the 70th percentile of 645 internal medicine providers in District of Columbia.

See all internal medicine providers in District of Columbia

Medicare billing

Part B allowed, 2024
$115,624
Medicare patients
335
Services billed
1,149

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide23$38,447
JardianceEmpagliflozin25$25,017
JanuviaSitagliptin Phosphate13$16,917
Atorvastatin Calcium248$2,870
Rosuvastatin Calcium104$1,782
Amlodipine Besylate178$1,551
Tamsulosin Hcl67$1,113
Levothyroxine Sodium102$1,100
Losartan Potassium80$925
Metformin Hcl91$889
Omeprazole34$760
ValacyclovirValacyclovir Hcl17$714
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen11$686
SynthroidLevothyroxine Sodium17$680
Fluticasone Propionate23$588

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$78$38,44723 claims
MerckJanuvia$28$16,91713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 645 internal medicine providers in District of Columbia.

Other internal medicine in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →